Source: Healio.com/hematology-oncology, April 2016
NEW YORK — Christian Blank, MD, PhD, staff member in medical oncology and group leader of the division of immunology at Netherlands Cancer Institute, reviewed new checkpoint targets during a presentation at HemOnc Today Melanoma and Cutaneous Malignancies.
Evidence suggests checkpoint modulation will be the backbone of melanoma therapy, Blank said.
click here to view video and read the full original article
“We have treated a lot of patients with immunotherapy and we have treated a lot of patients with targeted therapy,” Blank said. “I am convinced that, for long-term benefit, we need immunotherapy.”